Replay available

Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call

Quest Diagnostics Incorporated (NYSE: DGX) Q2 2026 earnings conference call, held 2026-07-23. Replay captured from the company's public earnings webcast.

Thu, July 23, 2026 at 8:30 AMendedReplay
Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dan Haemmerle

Vice President of Finance

Jim Davis

Chairman, Chief Executive Officer and President

Sam Samad

Chief Financial Officer

Erin Wright

Analyst at Morgan Stanley

Lisa Gill

Analyst at JP Morgan

Michael Cherney

Analyst at Leerink Partners

Michael Ruskin

Analyst at Bank of America

Anne Hines

Analyst at Mizuho Securities

Anna Krzywinski

Analyst at Barclays

Tycho Peterson

Analyst at Jefferies

Elizabeth Anderson

Analyst at Evercore ISI

Pito Chickering

Analyst at Deutsche Bank

Patrick Donnelly

Analyst at Citi

David Westenberg

Analyst at Piper Sandler

Replay transcript excerpt

Welcome to the Quest Diagnostics second quarter 2026 conference call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and the question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission, or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. I'd now like to introduce Dan Haemmerle, Vice President of Finance for Quest Diagnostics. Please go ahead, sir. Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President, and Sam Samad, our Chief Financial Officer. Also joining us is Dominique Chokshi, our new Head of Investor Relations who joined Quest Diagnostics last week. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long-term outlook projections including consolidated revenue growth Revenue Growth from Acquisitions, Organic Revenue Growth, and Adjusted Earnings Growth are compound annual growth rates. Now, here's Jim Davis. Thanks, Dan, and good morning, everyone. Be...

More from Quest Diagnostics Incorporated